{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:20:48Z","timestamp":1773832848207,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.diabet.2021.101299","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T16:13:58Z","timestamp":1635610438000},"page":"101299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes"],"prefix":"10.1016","volume":"48","author":[{"given":"Jui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-3351","authenticated-orcid":false,"given":"Hon-Yen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Liong","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2021.101299_bib0001","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2021.101299_bib0002","article-title":"Prevalence and risk factors for chronic kidney disease in Belize: a population-based survey","volume":"1","author":"Lin","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.diabet.2021.101299_bib0003","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2021.101299_bib0004","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabet.2021.101299_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101299_bib0006","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","article-title":"Therapeutic strategies based on glucagon-like peptide 1","volume":"53","author":"Deacon","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2021.101299_bib0007","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2021.101299_bib0008","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.diabet.2018.05.007","article-title":"Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: results of randomized controlled trials and observational studies","volume":"44","author":"Scheen","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2021.101299_bib0009","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/184075","article-title":"Gender differences and the trend in the acute myocardial infarction: a 10-year nationwide population-based analysis","volume":"2012","author":"Yang","year":"2012","journal-title":"Sci World J"},{"key":"10.1016\/j.diabet.2021.101299_bib0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00592-014-0663-2","article-title":"Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study","volume":"51","author":"Kim","year":"2014","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2021.101299_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124287","article-title":"Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study","volume":"10","author":"Seong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2021.101299_bib0012","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4093\/dmj.2015.39.3.247","article-title":"Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean health insurance claims database","volume":"39","author":"Suh","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabet.2021.101299_bib0013","article-title":"cardiovascular outcomes of sitagliptin in type 2 diabetic patients with acute myocardial infarction, a population-based cohort study in Taiwan","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2021.101299_bib0014","first-page":"39","article-title":"Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus","author":"Zeng","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.diabet.2021.101299_bib0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2014.09.038","article-title":"Sitagliptin and the risk of hospitalization for heart failure: a population-based study","volume":"177","author":"Wang","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2021.101299_bib0016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2014.12.029","article-title":"Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study","volume":"181","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2021.101299_bib0017","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.diabet.2021.101299_bib0018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2021.101299_bib0019","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2021.101299_bib0020","unstructured":"U.S. Food and Drug Administration. FDA drug safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes. [Accessed Oct 3, 2021]."},{"key":"10.1016\/j.diabet.2021.101299_bib0021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4093\/dmj.2020.0057","article-title":"Cardiovascular safety of sodium glucose cotransporter 2 inhibitors as add-on to metformin monotherapy in patients with type 2 diabetes mellitus","volume":"45","author":"Jeon","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabet.2021.101299_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-020-01078-5","article-title":"Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study","volume":"19","author":"Thein","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2021.101299_bib0023","doi-asserted-by":"crossref","first-page":"adv00390","DOI":"10.2340\/00015555-3758","article-title":"Risk of skin cancer among patients with chronic kidney disease treated with ultraviolet B phototherapy for uraemic pruritus: a nationwide cohort study","volume":"101","author":"Ko","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.diabet.2021.101299_bib0024","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.05.020","article-title":"Effects of higher quality of care on initiation of long-term dialysis in patients with CKD and diabetes","volume":"70","author":"Wu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2021.101299_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2261-14-38","article-title":"Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan","volume":"14","author":"Lin","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.diabet.2021.101299_bib0026","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2021.101299_bib0027","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/. [Accessed Oct 3, 2021]."},{"key":"10.1016\/j.diabet.2021.101299_bib0028","first-page":"721","article-title":"Validating the adapted diabetes complications severity index in claims data","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.diabet.2021.101299_bib0029","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jdiacomp.2014.05.011","article-title":"Risk of hospitalization and healthcare cost associated with diabetes complication severity index in Taiwan's national health insurance research database","volume":"28","author":"Chen","year":"2014","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.diabet.2021.101299_bib0030","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat - Simul Comput"},{"key":"10.1016\/j.diabet.2021.101299_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003957","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study","volume":"10","author":"Kim","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.diabet.2021.101299_bib0032","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M15-0308","article-title":"Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus","volume":"163","author":"Ou","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2021.101299_bib0033","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2016.06.125","article-title":"No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan","volume":"220","author":"Chang","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2021.101299_bib0034","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc15-0764","article-title":"Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study","volume":"39","author":"Fu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2021.101299_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/M15-2568","article-title":"Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study","volume":"164","author":"Toh","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2021.101299_bib0036","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2021.101299_bib0037","first-page":"157","article-title":"Accuracy of diabetes diagnosis in health insurance claims data in Taiwan","volume":"104","author":"Lin","year":"2005","journal-title":"J Formos Med Assoc"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363621000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363621000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:58:03Z","timestamp":1761130683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363621000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1262363621000823"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2021.101299","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2021.101299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101299"}}